At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:NVO) shared an abstract with data from the company’s next-generation weight loss candidate, amycretin.
Earlier today, Novo Nordisk announced that its weight-loss drug liraglutide is safe and effective for children as young as six.
The company-funded study revealed a 7.4% reduction in body mass index for children aged 6 to 12 who used the injectable pens over a year compared to a placebo group.
Amycretin is a novel protein-based unimolecular amylin (regulates hunger) and GLP-1 receptor co-agonist for once-daily oral administration.
GLP-1 (produced in the small intestine to regulate blood sugar) is the same hormone targeted by other weight loss drugs like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide).
In a ...
